Dr. Denis Garceau directs BELLUS Health’s drug development program, from toxicology to clinical evaluation through to approval of new products, and has been with the Company since March 1997. He is also currently the Auven Therapeutics Global Project Leader for the Kiacta™ development program.From 1986 to 1997, as a clinical scientist and product team leader for Hoechst Marion Roussel (now Sanofi-Aventis), Dr. Garceau successfully oversaw North American clinical programs and participated in global clinical development steering committees. He was responsible for developing clinical operating plans, designing clinical protocols, and supervising clinical trials. In 1985-86, Dr. Garceau completed a post-doctorate Research fellowship in Pharmacology at Merck Frosst Canada.


Dr. Garceau holds a Ph.D. in Pharmacology from the Université de Montréal, and is currently a guest lecturer for the faculty of pharmacy of the Université de Montréal and Université Laval.


Recent Posts

Forward Looking Statements

Certain statements contained in this blog, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond BELLUS Health Inc.'s control. Such risks include but are not limited to: the ability to obtain financing, the impact of general economic conditions, general conditions in the pharmaceutical industry, changes in the regulatory environment in the jurisdictions in which the BELLUS Health Inc. does business, stock market volatility, fluctuations in costs, changes to the competitive environment due to consolidation, achievement of forecasted burn rate, potential payments in relation to indemnity agreements, achievement of forecasted clinical trial milestones, and that actual results may vary once the final and quality-controlled verification of data and analyses has been completed. In addition, the length of the KIACTA™ Phase III Confirmatory Study is dependent upon many factors, including patient drop-out rate and occurrence of clinical endpoint events, and the sharing of proceeds between Auven Therapeutics and BELLUS Health Inc. from potential future revenue of KIACTA™ is dependent upon a number of factors, including the quantum of proceeds. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this blog. These statements speak only as of the date made and BELLUS Health Inc. is under no obligation and disavows any intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation. Please see BELLUS Health Inc.'s public fillings including the Annual Information Form for further risk factors that might affect BELLUS Health Inc. and its business.

This Blog is official and sanctioned by BELLUS Health Inc. | See Legal Disclaimer | See Privacy Policy

Get BELLUS Health Inc. Blog Post Alerts